GCP
ALNY icon

Garda Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Garda Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-30,500
Closed -$9.95M – 46
2025
Q2 		$9.95M Sell
30,500
-1,100
-3% -$304K 0.24% 112
2025
Q1 		$8.53M Buy
31,600
+5,700
+22% +$1.46M 0.22% 137
2024
Q4 		$6.09M Buy
25,900
+3,800
+17% +$999K 0.44% 67
2024
Q3 		$6.08M Buy
+22,100
New +$5.75M 0.17% 168

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Garda Capital Partners's ALNY Position: Q1 2025 in Review

Garda Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 8,143 shares — an estimated $2.09M sold.

Garda Capital Partners first reported a position in ALNY in Q4 2024 and held it in 1 quarter. The position peaked at $1.92M in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Garda Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Garda Capital Partners sold 8,143 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $2.09M.
  • Garda Capital Partners first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Garda Capital Partners's Alnylam Pharmaceuticals position peaked at $1.92M in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Garda Capital Partners's 13F filing for Q1 2025, filed 14 May 2025.